Ipsen M, Zhang Y, Dragsted N, Han C, Mulvany M J
Department of Pharmacology, University of Aarhus, Aarhus C, Denmark.
Eur J Pharmacol. 1997 Oct 1;336(1):29-35. doi: 10.1016/s0014-2999(97)01242-9.
We have investigated the adrenergic antagonist effect of the antipsychotic sertindole in rat resistance vessels and in membranes of HEK293 cells transfected with alpha1-adrenoceptors. Segments of rat mesenteric small arteries or rat aorta were mounted on a myograph for isometric tension recording. In mesenteric small arteries, specific alpha1A-adrenoceptor antagonists (5-methyl urapidil and WB-4101 (2-(2,6-dimethoxyphenoxyethyl) aminomethyl-1,4-benzodioxane)) inhibited phenylephrine responses with high affinity (pA2 9.1 and 9.5, respectively). Chlorethylclonidine (alpha1B- and alpha1D-adrenoceptor antagonist) and BMY7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro [4,5] decane-7,9-dione dihydrochloride, alpha1D-adrenoceptor antagonist) had little effect. This indicated that the adrenoceptor subtype in the mesenteric small arteries was of the alpha1A subtype. Sertindole inhibited the phenylephrine response of mesenteric small arteries (pA2 9.0), but had little effect on the phenylephrine response of aorta (which lacks alpha1A-adrenoceptors). The specific action of sertindole on alpha1A-adrenoceptors was supported by experiments with membranes of HEK293 (human embryonic kidney) cells transfected with the alpha1A-, alpha1B- and alpha1D-adrenoceptors. Here, with concurrent incubation, sertindole showed selective competitive inhibition of BE2254 (2-beta(4-hydroxyphenyl)-ethylaminomethyl)-tetralone) binding to alpha1A-adrenoceptors (Ki 8.9), compared to alpha1B-adrenoceptors (Ki 7.1) and alpha1D-adrenoceptors (Ki 6.8). Despite the apparent competitive action sertindole, it was not possible to wash out its antagonist effect within 6 h in the functional phenylephrine concentration-response experiments. Furthermore, in the membranes of HEK293 cells transfected with the alpha1A-adrenoceptors, binding of [125I]BE2254 was reduced by 45% following preincubation with sertindole (1 nM). We conclude that the alpha-adrenoceptors of rat mesenteric small arteries are of the alpha1A-type, and that sertindole is a specific pseudo-irreversible competitive antagonist of this adrenoceptor subtype.
我们研究了抗精神病药物舍吲哚在大鼠阻力血管以及转染了α1 -肾上腺素能受体的HEK293细胞膜中的肾上腺素能拮抗作用。将大鼠肠系膜小动脉或大鼠主动脉段安装在肌动描记器上以记录等长张力。在肠系膜小动脉中,特异性α1A -肾上腺素能受体拮抗剂(5 -甲基乌拉地尔和WB - 4101(2 -(2,6 -二甲氧基苯氧基乙基)氨基甲基 - 1,4 -苯并二恶烷))以高亲和力抑制去氧肾上腺素反应(pA2分别为9.1和9.5)。氯乙基可乐定(α1B -和α1D -肾上腺素能受体拮抗剂)和BMY7378(8 - [2 - [4 -(2 -甲氧基苯基) - 1 -哌嗪基]乙基] - 8 -氮杂螺[4,5]癸烷 - 7,9 -二酮二盐酸盐,α1D -肾上腺素能受体拮抗剂)作用甚微。这表明肠系膜小动脉中的肾上腺素能受体亚型为α1A亚型。舍吲哚抑制肠系膜小动脉对去氧肾上腺素的反应(pA2为9.0),但对主动脉(缺乏α1A -肾上腺素能受体)对去氧肾上腺素的反应影响甚微。转染了α1A -、α1B -和α1D -肾上腺素能受体的HEK293(人胚肾)细胞膜实验支持了舍吲哚对α1A -肾上腺素能受体的特异性作用。在此实验中,同时孵育时,与α1B -肾上腺素能受体(Ki为7.1)和α1D -肾上腺素能受体(Ki为6.8)相比,舍吲哚显示出对BE2254(2 -β(4 -羟基苯基) -乙氨基甲基) -四氢萘酮)与α1A -肾上腺素能受体结合的选择性竞争性抑制(Ki为8.9)。尽管舍吲哚表现出明显的竞争性作用,但在功能性去氧肾上腺素浓度 -反应实验中,6小时内无法洗脱其拮抗作用。此外,在用舍吲哚(1 nM)预孵育后,转染了α1A -肾上腺素能受体的HEK293细胞膜中,[125I]BE2254的结合减少了45%。我们得出结论,大鼠肠系膜小动脉的α -肾上腺素能受体为α1A类型,并且舍吲哚是该肾上腺素能受体亚型的特异性拟不可逆竞争性拮抗剂。